| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Afamelanotide | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | | | Afamelanotide | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Afamelanotide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | | Afamelanotide | hsa00061 | Fatty acid biosynthesis | 4.83E-02 | 1 | P33121 | ACSL1 | More | | | Afamelanotide | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Afamelanotide | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | | Afamelanotide | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Afamelanotide | hsa00220 | Arginine biosynthesis | 1.21E-02 | 1 | P15104 | GLUL | More | | | Afamelanotide | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Afamelanotide | hsa00280 | Valine, leucine and isoleucine degradation | 4.31E-02 | 2 | P26440, Q02252 | IVD, ALDH6A1 | More | | | Afamelanotide | hsa00500 | Starch and sucrose metabolism | 2.61E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Afamelanotide | hsa00513 | Various types of N-glycan biosynthesis | 4.83E-02 | 1 | Q9NR34 | MAN1C1 | More | | | Afamelanotide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | | Afamelanotide | hsa00591 | Linoleic acid metabolism | 4.83E-02 | 1 | P11712 | CYP2C9 | More | | | Afamelanotide | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | | | Afamelanotide | hsa00750 | Vitamin B6 metabolism | 4.45E-02 | 1 | O00764 | PDXK | More | | | Afamelanotide | hsa00830 | Retinol metabolism | 4.09E-02 | 2 | O75911, P11712 | DHRS3, CYP2C9 | More | | | Afamelanotide | hsa00860 | Porphyrin and chlorophyll metabolism | 5.29E-03 | 2 | P53004, P30043 | BLVRA, BLVRB | More | | | Afamelanotide | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | | Afamelanotide | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | | Afamelanotide | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.17E-02 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | | Afamelanotide | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Afamelanotide | hsa01230 | Biosynthesis of amino acids | 1.59E-04 | 6 | P51854, P60891, Q99707, P50213, P15104, P37837 | TKTL1, PRPS1, MTR, IDH3A, GLUL, TALDO1 | More | | | Afamelanotide | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | | Afamelanotide | hsa01522 | Endocrine resistance | 8.47E-03 | 7 | P14780, P22694, Q9UM47, P04637, P42773, P10415, Q13323 | MMP9, PRKACB, NOTCH3, TP53, CDKN2C, BCL2, BIK | More | | | Afamelanotide | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Afamelanotide | hsa01524 | Platinum drug resistance | 4.42E-02 | 3 | P10415, Q13489, P23025 | BCL2, BIRC3, XPA | More | | | Afamelanotide | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | | Afamelanotide | hsa03013 | RNA transport | 3.52E-02 | 4 | P52298, O14893, O14602, P78345 | NCBP2, GEMIN2, EIF1AY, RPP38 | More | | | Afamelanotide | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | | Afamelanotide | hsa03050 | Proteasome | 3.05E-02 | 1 | P55036 | PSMD4 | More | | | Afamelanotide | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | | | Afamelanotide | hsa03450 | Non-homologous end-joining | 4.32E-02 | 1 | Q9NP87 | POLM | More | | | Afamelanotide | hsa04015 | Rap1 signaling pathway | 9.14E-03 | 2 | P06213, O00522 | INSR, KRIT1 | More | | | Afamelanotide | hsa04064 | NF-kappa B signaling pathway | 1.21E-04 | 13 | P10415, Q13489, P51617, O00463, Q13546, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q8WV28, Q13315, P24522 | BCL2, BIRC3, IRAK1, TRAF5, RIPK1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, BLNK, ATM, GADD45A | More | | | Afamelanotide | hsa04071 | Sphingolipid signaling pathway | 1.24E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2, P01042 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2, KNG1 | More | | | Afamelanotide | hsa04080 | Neuroactive ligand-receptor interaction | 9.13E-05 | 14 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P25116, Q01726, P41968, P21462, P21730, Q16581, P07550, P01042 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, F2R, MC1R, MC3R, FPR1, C5AR1, C3AR1, ADRB2, KNG1 | More | | | Afamelanotide | hsa04110 | Cell cycle | 2.75E-04 | 9 | P30260, P06493, O75293, P04637, P49918, P30304, P33981, P42773, P01106 | CDC27, CDK1, GADD45B, TP53, CDKN1C, CDC25A, TTK, CDKN2C, MYC | More | | | Afamelanotide | hsa04115 | p53 signaling pathway | 2.54E-02 | 3 | O15151, Q13315, P10415 | MDM4, ATM, BCL2 | More | | | Afamelanotide | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | | Afamelanotide | hsa04142 | Lysosome | 2.87E-03 | 3 | Q99437, P25774, Q99523 | ATP6V0B, CTSS, SORT1 | More | | | Afamelanotide | hsa04145 | Phagosome | 1.13E-03 | 11 | O75015, Q15080, P14598, Q13509, P68371, Q99437, P05164, O60603, P35443, P13765, P25774 | FCGR3B, NCF4, NCF1, TUBB3, TUBB2C, ATP6V0B, MPO, TLR2, THBS4, HLA-DOB, CTSS | More | | | Afamelanotide | hsa04151 | PI3K-Akt signaling pathway | 4.57E-02 | 3 | P04637, Q96BR1, P56279 | TP53, SGK3, TCL1A | More | | | Afamelanotide | hsa04215 | Apoptosis - multiple species | 3.01E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | | Afamelanotide | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Afamelanotide | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Afamelanotide | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | | Afamelanotide | hsa04380 | Osteoclast differentiation | 1.81E-02 | 4 | Q9UQC2, Q16539, Q8WV28, Q15080 | GAB2, MAPK14, BLNK, NCF4 | More | | | Afamelanotide | hsa04510 | Focal adhesion | 4.60E-02 | 4 | P16144, Q15942, Q13489, P10415 | ITGB4, ZYX, BIRC3, BCL2 | More | | | Afamelanotide | hsa04540 | Gap junction | 7.81E-03 | 3 | Q13509, P68371, Q9NRA1 | TUBB3, TUBB2C, PDGFC | More | | | Afamelanotide | hsa04610 | Complement and coagulation cascades | 2.20E-04 | 4 | P25116, P01042, P0C0L4, Q16581 | F2R, KNG1, C4A, C3AR1 | More | | | Afamelanotide | hsa04612 | Antigen processing and presentation | 7.40E-07 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.7 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.874 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.743 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.738 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.867 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.867 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.837 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P14780 | MMP9 | Matrix metalloproteinase-9 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.792 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.721 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.741 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.742 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 |
| | Afamelanotide | hsa04613 | Neutrophil extracellular trap formation | 5.09E-05 | 18 | P17252, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, Q6FI13, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Afamelanotide | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | | Afamelanotide | hsa04625 | C-type lectin receptor signaling pathway | 4.80E-02 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | | Afamelanotide | hsa04640 | Hematopoietic cell lineage | 3.65E-03 | 13 | P13612, P21926, P14778, P27930, P15144, P11836, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, CD9, IL1R1, IL1R2, ANPEP, MS4A1, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | | Afamelanotide | hsa04650 | Natural killer cell mediated cytotoxicity | 5.08E-06 | 10 | P01375, P78314, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Afamelanotide | hsa04657 | IL-17 signaling pathway | 3.29E-04 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | | Afamelanotide | hsa04658 | Th1 and Th2 cell differentiation | 2.46E-04 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | | | Afamelanotide | hsa04659 | Th17 cell differentiation | 3.13E-02 | 8 | Q04759, Q16539, P13765, P14778, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, HLA-DOB, IL1R1, TBX21, GATA3, CD3G, CD247 | More | | | Afamelanotide | hsa04660 | T cell receptor signaling pathway | 6.57E-06 | 11 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.767 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q04759 | PRKCQ | Protein kinase C theta type | -0.787 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | | P14780 | MMP9 | Matrix metalloproteinase-9 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.792 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.806 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.855 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.812 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.745 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.719 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.742 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.793 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.816 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.75 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 |
| | Afamelanotide | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 5 | O75015, P06396, O14494, P14598, P17252 | FCGR3B, GSN, PLPP1, NCF1, PRKCA | More | | | Afamelanotide | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Afamelanotide | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Afamelanotide | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | Q99523 | SORT1 | More | | | Afamelanotide | hsa04912 | GnRH signaling pathway | 4.72E-02 | 4 | Q16539, Q9Y6R4, Q14643, P22694 | MAPK14, MAP3K4, ITPR1, PRKACB | More | | | Afamelanotide | hsa04913 | Ovarian steroidogenesis | 2.45E-03 | 3 | P42330, P22694, P06213 | AKR1C3, PRKACB, INSR | More | | | Afamelanotide | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | | Afamelanotide | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | | Afamelanotide | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | | | Afamelanotide | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Afamelanotide | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Afamelanotide | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Afamelanotide | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | | | Afamelanotide | hsa04940 | Type I diabetes mellitus | 4.18E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | | Afamelanotide | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | | | Afamelanotide | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | | Afamelanotide | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | | Afamelanotide | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | | Afamelanotide | hsa04979 | Cholesterol metabolism | 8.29E-03 | 1 | Q99523 | SORT1 | More | | | Afamelanotide | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | | | Afamelanotide | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Afamelanotide | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | | Afamelanotide | hsa05131 | Shigellosis | 1.80E-02 | 5 | Q13546, Q9UDY8, Q12778, Q13315, P10415 | RIPK1, MALT1, FOXO1, ATM, BCL2 | More | | | Afamelanotide | hsa05132 | Salmonella infection | 4.85E-02 | 4 | Q13546, P10415, Q13509, P68371 | RIPK1, BCL2, TUBB3, TUBB2C | More | | | Afamelanotide | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | | Afamelanotide | hsa05140 | Leishmaniasis | 7.94E-08 | 11 | P13612, O75015, P14598, P13765, O60603, P25963, P01375, P29350, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, PTPN6, MAPK14, IRAK1, NCF4 | More | | | Afamelanotide | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | | Afamelanotide | hsa05144 | Malaria | 1.22E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | | Afamelanotide | hsa05145 | Toxoplasmosis | 1.28E-02 | 4 | Q16539, P10415, Q13489, P13765 | MAPK14, BCL2, BIRC3, HLA-DOB | More | | | Afamelanotide | hsa05146 | Amoebiasis | 9.75E-05 | 10 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | | Afamelanotide | hsa05150 | Staphylococcus aureus infection | 1.65E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P49913 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, CAMP | More | | | Afamelanotide | hsa05152 | Tuberculosis | 6.04E-04 | 12 | Q99437, O75015, P48382, O60603, P01375, P10415, P13765, P25774, P49913, Q9UDY8, Q16539, P51617 | ATP6V0B, FCGR3B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CTSS, CAMP, MALT1, MAPK14, IRAK1 | More | | | Afamelanotide | hsa05202 | Transcriptional misregulation in cancer | 2.78E-06 | 22 | Q12778, Q15532, P41732, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P68431, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, HDAC1, HDAC2, LYL1, GADD45A | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P22894 | MMP8 | Neutrophil collagenase | Q12778 | FOXO1 | Forkhead box protein O1 | -0.72 | | P22894 | MMP8 | Neutrophil collagenase | Q15532 | SS18 | Protein SSXT | -0.867 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q15532 | SS18 | Protein SSXT | -0.829 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41732 | TSPAN7 | Tetraspanin-7 | 0.703 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P14780 | MMP9 | Matrix metalloproteinase-9 | 1 | | P22894 | MMP8 | Neutrophil collagenase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.882 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.942 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.851 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.924 | | P22894 | MMP8 | Neutrophil collagenase | P14923 | JUP | Junction plakoglobin | -0.809 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.7 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.921 | | P22894 | MMP8 | Neutrophil collagenase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.843 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.913 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.751 | | P22894 | MMP8 | Neutrophil collagenase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.765 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.832 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.758 | | P22894 | MMP8 | Neutrophil collagenase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.806 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.712 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | O15550 | UTX | Lysine-specific demethylase 6A | 0.73 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | | P22894 | MMP8 | Neutrophil collagenase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.821 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | | P22894 | MMP8 | Neutrophil collagenase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.821 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | | P22894 | MMP8 | Neutrophil collagenase | P05164 | MPO | Myeloperoxidase | 0.905 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | P05164 | MPO | Myeloperoxidase | 0.711 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.858 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.767 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | | P22894 | MMP8 | Neutrophil collagenase | P08246 | ELA2 | Neutrophil elastase | 0.985 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.752 | | P22894 | MMP8 | Neutrophil collagenase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.778 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.765 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.812 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.9 | | Q16581 | C3AR1 | C3a anaphylatoxin chemotactic receptor | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | -0.79 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P12980 | LYL1 | Protein lyl-1 | 0.716 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12980 | LYL1 | Protein lyl-1 | 0.782 | | P14780 | MMP9 | Matrix metalloproteinase-9 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.765 | | P22894 | MMP8 | Neutrophil collagenase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.766 | | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.801 |
| | Afamelanotide | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Afamelanotide | hsa05215 | Prostate cancer | 3.03E-02 | 3 | P10415, Q12778, Q9NRA1 | BCL2, FOXO1, PDGFC | More | | | Afamelanotide | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Afamelanotide | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Afamelanotide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | | | Afamelanotide | hsa05310 | Asthma | 9.08E-04 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | | Afamelanotide | hsa05321 | Inflammatory bowel disease | 5.07E-08 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | | Afamelanotide | hsa05322 | Systemic lupus erythematosus | 2.82E-02 | 8 | O75015, P08246, P08311, P01375, P10747, P13765, Q6FI13, P05455 | FCGR3B, ELA2, CTSG, TNF, CD28, HLA-DOB, H2AC18; H2AC19, SSB | More | | | Afamelanotide | hsa05332 | Graft-versus-host disease | 4.70E-06 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | | Afamelanotide | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Afamelanotide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
|
